BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 26561843)

  • 1. Bone markers in craniofacial bone deformations and dysplasias.
    Seifert M; Nelke KH; Noczyńska A; Łysenko L; Kubacka M; Gerber H
    Postepy Hig Med Dosw (Online); 2015 Oct; 69():1176-81. PubMed ID: 26561843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Paget's disease: case report].
    Wegierska M; Ignaczak P; Zalewska J; Jeka S
    Ann Acad Med Stetin; 2011; 57(3):64-9; discussion 69. PubMed ID: 23383549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paget's disease with craniofacial and skeletal bone involvement.
    Rai NP; Anekar J; Mustafa SM; Devang Divakar D
    BMJ Case Rep; 2016 Sep; 2016():. PubMed ID: 27587747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates.
    Alvarez L; Peris P; Guañabens N; Vidal S; Ros I; Pons F; Filella X; Monegal A; Muñoz-Gomez J; Ballesta AM
    Arthritis Rheum; 2003 Mar; 48(3):824-8. PubMed ID: 12632438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paget's disease of bone, osteogenesis imperfecta, and fibrous dysplasia.
    Smith R
    Br Med J; 1977 Feb; 1(6057):365-7. PubMed ID: 837101
    [No Abstract]   [Full Text] [Related]  

  • 6. Biochemical markers of bone turnover in Paget's disease.
    Russell RG; Beard DJ; Cameron EC; Douglas DL; Forrest AR; Guilland-Cumming D; Paterson AD; Poser J; Preston CJ; Milford-Ward A; Woodhead S; Kanis JA
    Metab Bone Dis Relat Res; 1981; 3(4-5):255-62. PubMed ID: 6220191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemical markers of bone turnover in Paget's disease of bone.
    Eastell R
    Bone; 1999 May; 24(5 Suppl):49S-50S. PubMed ID: 10321928
    [No Abstract]   [Full Text] [Related]  

  • 8. Fibrous Dysplasia, Paget's Disease of Bone, and Other Uncommon Sclerotic Bone Lesions of the Craniofacial Bones.
    Van de Voorde N; Mortier GR; Vanhoenacker FM
    Semin Musculoskelet Radiol; 2020 Oct; 24(5):570-578. PubMed ID: 33036044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human calcitonin in the treatment of Paget's bone disease.
    Woodhouse NJ; Bordier P; Fisher M; Joplin GF; Reiner M; Kalu DN; Foster GV; MacIntyre I
    Lancet; 1971 Jun; 1(7710):1139-43. PubMed ID: 4102856
    [No Abstract]   [Full Text] [Related]  

  • 10. Paget's disease and fibrous dysplasia.
    Wallach S
    Curr Opin Rheumatol; 1991 Jun; 3(3):472-80. PubMed ID: 1883702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term treatment of Paget's disease of bone with salmon calcitonin.
    Sturtridge WC; Harrison JE; Wilson DR
    Can Med Assoc J; 1977 Nov; 117(9):1031-4. PubMed ID: 562231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [How to evaluate the activity of Paget's disease in clinical practice and which patients should be treated?].
    Reiner JC; Bontoux-Carre E; Seret P; Villayleck S
    Rev Rhum Mal Osteoartic; 1984 Oct; 51(9):463-8. PubMed ID: 6505596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthetic salmon calcitonin. Treatment of Paget's disease and osteogenesis imperfecta.
    Goldfield EB; Braiker BM; Prendergast JJ; Kolb FO
    JAMA; 1972 Sep; 221(10):1127-9. PubMed ID: 4679000
    [No Abstract]   [Full Text] [Related]  

  • 14. Remissions in Paget's disease produced by human synthetic calcitonin (calcitonin M).
    Woodhouse NJ; Reiner M; Kalu DN; Galante L; Joplin GF; MacIntyre I
    Clin Sci; 1970 Sep; 39(3):9P-10P. PubMed ID: 5459177
    [No Abstract]   [Full Text] [Related]  

  • 15. Relationship between biochemical markers of bone turnover and bone scintigraphic indices in assessment of Paget's disease activity.
    Alvarez L; Peris P; Pons F; Guañabens N; Herranz R; Monegal A; Bedini JL; Deulofeu R; Martínez de Osaba MJ; Muñoz-Gómez J; Ballesta AM
    Arthritis Rheum; 1997 Mar; 40(3):461-8. PubMed ID: 9082934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Skeletal turnover and total body elemental composition during extended calcitonin treatment of Paget's disease.
    Wallach S; Avramides A; Flores A; Bellavia J; Cohn S
    Metabolism; 1975 Jun; 24(6):745-53. PubMed ID: 1128238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Paget's disease of bone (osteitis deformans) with sodium etidronate (EHDP).
    Rashid M; Khairi A; Johnston C
    Clin Orthop Relat Res; 1977; (127):94-105. PubMed ID: 410576
    [No Abstract]   [Full Text] [Related]  

  • 18. Genetic disorders and bone affecting the craniofacial skeleton.
    Chacon GE; Ugalde CM; Jabero MF
    Oral Maxillofac Surg Clin North Am; 2007 Nov; 19(4):467-74, v. PubMed ID: 18088898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Paget disease of the skeleton. Internal medicine aspects].
    Ziegler R; Baldauf G
    Radiologe; 1984 Sep; 24(9):401-7. PubMed ID: 6238341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Paget's disease of the skeleton].
    Ziegler R
    Internist (Berl); 1990 Dec; 31(12):763-8. PubMed ID: 2289866
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.